Last week’s Enhanced Games, an Olympics‑lite event for athletes using performance‑enhancing drugs, aimed to showcase human ingenuity. Instead, the company’s shares plunged 70% from their $10 IPO price, halving in value within weeks.

Enhanced’s market entry via a SPAC exposed three critical flaws. Investors reclaimed $200 million, leaving only $4 million in cash, while many sold bonus shares immediately. SPACs routinely lose 85% of value post‑listing, a trend that has shaken investor confidence.

Backers project $175 million in revenue next year from sponsorships, supplements and prescription peptides. Even with a three‑times multiple, Enhanced could reach $525 million, or $900 million when compared to the Atlanta Braves. Yet filings warn of “substantial doubt” over a 12‑month survival.

Donald Trump Jr. profited by converting early preferred shares at roughly $2 each, turning a modest stake into a five‑fold return. The episode underscores how financial mechanisms can distort perceived gains, mirroring concerns about drug‑enhanced competition.